An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening

We’re monitoring today’s meeting of the FDA advisory committee on Palforzia, a novel but controversial treatment that uses calibrated quantities of ingested peanut powder to protect people against severe peanut allergy. Check back here often for updates throughout the day.

Let’s get this FDA panel started

 The FDA advisory panel will be a pivotal moment for Aimmune Therapeutics (AIMT), the biopharma company that developed the new treatment. If approved, Palforzia (formerly AR101) will be the first protective therapy for peanut allergy and the start of what Aimmune hopes will be